SCHEMBL139351

SCHEMBL139351

CCCCCCCCN=Cc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
NR4A1 P22736 1/20 0.46
MAOA P21397 2/20 0.45
TOP2A P11388 2/20 0.43
LMNA P02545 3/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
USP2 O75604 2/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
HSP90AA1 P07900 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
G6PC1 P35575 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10321703 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL16353929 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL10321597 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL27112153 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL16353859 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL342149 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL10321022 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL16353930 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL10320909 1.00 CYP1A2 (0.56) CYP1A2CYP2C19NR4A1MAOATOP2A
SCHEMBL832504 0.98 CYP1A2 (0.53) CYP1A2CYP2C19NR4A1MAOATOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3042645-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2025-03-12 EP claimed
US-11357708-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2022-06-14 US claimed
EP-3042645-B1 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2022-04-27 EP claimed
US-20180318178-A1 DENTAL COMPOSITES WITH IMPROVED STORAGE STABILITY IVOCLAR VIVADENT AG (LI) 2018-11-08 US claimed
EP-3042645-A1 Dental composites with improved storage stability Ivoclar Vivadent AG (LI) 2016-07-13 EP claimed
EP-4066902-B1 ZWITTERIONIC COMPOUND AND PRODUCTION METHOD AND USE FOR SAME UNIV TOKUSHIMA (JP) 2026-03-18 EP disclosed
US-12522678-B2 Zwitterion compound and production method and use for same TOKUSHIMA UNIVERSITY (JP) 2026-01-13 US disclosed
US-20250213436-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL MITSUI CHEMICALS, INC. (JP) 2025-07-03 US disclosed
EP-3042645-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2025-03-12 EP disclosed
EP-4501974-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT AND DENTAL MATERIAL Mitsui Chemicals, Inc. (JP) 2025-02-05 EP disclosed
US-20250003961-A1 BASE MATERIAL FOR MANUFACTURING SENSOR FOR ANALYZING DETECTION TARGET, SENSOR FOR ANALYZING DETECTION TARGET, METHOD FOR ANALYZING DETECTION TARGET UNIV KOBE NAT UNIV CORP (JP) 2025-01-02 US disclosed
US-12134089-B2 Multimodal chromatographic media for protein separation DIONEX CORPORATION 2024-11-05 US disclosed
EP-1943278-A1 POLYMERIZATION PROCESS WITH CATALYST REACTIVATION CARNEGIE-MELLON UNIVERSITY (US) 2008-07-16 EP disclosed
US-20070219330-A1 Amide initiators WARWICK EFFECT POLYMERS LIMITED (GB) 2007-09-20 US disclosed
WO-2007083097-A1 LIVING RADICAL POLYMERISATION PROCESS WARWICK EFFECT POLYMERS LTD. (GB) 2007-07-26 WO disclosed
EP-1784430-A1 LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH , POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM. Warwick Effect Polymers Limited (GB) 2007-05-16 EP disclosed
WO-2007025310-A1 POLYMERIZATION PROCESS WITH CATALYST REACTIVATION CARNEGIE MELLON UNIVERSITY (US) 2007-03-01 WO disclosed
EP-1646661-A2 LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYPEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUNG OBTAINED THEREFROM Warwick Effect Polymers Limited (GB) 2006-04-19 EP disclosed
WO-2006003352-A1 LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM WARWICK EFFECT POLYMERS LIMITED (GB) 2006-01-12 WO disclosed
WO-2004113394-A2 LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYPEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM WARWICK EFFECT POLYMERS LIMITED (GB) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213436-A1 POLYMERIZATION ACCELERATOR, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL DNMT3L, CDK9, CDK6 CYP1A2 4538/4885CYP2C19 3379/4885NR4A1 3589/4885
US-12134089-B2 Multimodal chromatographic media for protein separation MAX, NEFM, MRPL21 CYP1A2 4805/4885CYP2C19 4530/4885NR4A1 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.